UIC research suggests new way to stop growth of cancer cells

November 11, 2002

A new study from the UIC College of Pharmacy may lead to the development of a drug to stop the growth of cancer cells. The study, published in the September issue of the journal Nature Medicine, was described in an editorial in the journal Nature as being among the most important recent findings in cancer-targeting research.

Dr. Lucio Miele, associate professor of biopharmaceutical sciences, and his team have developed a gene therapy approach as well as a potentially new use for a class of drugs known as GSIs, or gamma-secretase inhibitors, which are already under investigation as a treatment for Alzheimer's disease.

GSIs are drugs that block gamma secretase, an enzyme that produces a harmful protein in the brains of people with Alzheimer's. Miele's study shows that inhibiting gamma secretase also can block intercellular communications in cancer cells.

Cancer occurs when several genes within a cell are damaged. Earlier research has found that a type of gene called Ras is one of the most commonly damaged or inappropriately activated genes in human malignant tumors. Miele's research builds on that discovery.

His findings show that when damaged or excessively activated in human cells, Ras, through gamma secretase, activates a protein known as Notch-1, which in turn triggers a chain of events that allow cancer cells to grow.

"If we stop Notch, we stop Ras and, ultimately, we can stop cancers that depend on it for survival," Miele says.

Miele is one of several scientists who have been finding Notch gene alterations in various cancers. "But all that had been found so far was that the expression of these genes seemed increased in various tumors for unknown reasons," Miele said. "Nobody had described what causes this alteration, nor, most importantly, that these genes and proteins can be directly targeted for cancer treatment.

"The really exciting discovery for us is that you can stop cancer cells by just switching off these Notch genes or blocking the activation of notch proteins by gamma secretase," he said.

"This therapy works very well in model human cancer cells created in the laboratory, and it works even better in cells from an actual cervical cancer," Miele said, noting that this result was demonstrated both in the test tube and in experimental tumors formed by human cancer cells in mice. The test tube and mouse studies indicate that gamma secretase inhibitors warrant further investigation, he says. "This means there is a new potential target against which cancer drugs can be developed."

While Miele cautions that more studies are needed to establish which types of cancer could benefit from gamma secretase-blocking drugs or Notch-blocking gene therapy, he says his research and work from other laboratories indicate the potential for therapeutic applications to several types of human malignancies, including breast, cervical, head and neck, endometrial and renal cancers, some colon and lung cancers, aggressive melanomas, pleural mesotheliomas and certain lymphomas and leukemias.

Miele, a member of the UIC Cancer Center, expects to begin preliminary testing next year that may eventually lead to human clinical trials.

For more information about the UIC Cancer Center, visit www.uic.edu/com/cancer/.
-end-


University of Illinois at Chicago

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.